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Abstract
Introduction IL - ip  is a pro in flam m atory cytokine driv ing jo in t 
inflamm ation as w e ll as system ic s igns o f inflamm ation, such as 
fever and acu te  phase prote in production .
Methods A C Z 8 8 5 , a fu lly  human m onoclona l an tibody that 
neutralizes the b ioactiv ity  o f human IL - ip , w as generated to  
s tudy the  po ten t and long-lasting  neutralization of IL - ip  in 
m echan istic  animal m ode ls as w e ll as in a p roo f-o f-concep t 
s tudy in pa tients w ith  rheum atoid arthritis  (RA).
Results The m ouse IL-1 recep to r cross-reacts  w ith  human IL­
i  p, and it w as dem onstra ted  that A C Z 8 8 5  can com ple te ly  
suppress IL-1 p -m edia ted jo in t inflamm ation and cartilage 
destruc tion  in m ice. This observation p rom pted  us to  s tudy the 
safety, to le rab ility  and pharm acodynam ic activ ity  o f A C Z 8 8 5  in 
RA pa tien ts in a small p roo f-o f-concep t s tudy -  the  firs t to  be 
conduc ted  in humans. Patients w ith  active RA desp ite  treatm ent 
w ith  s tab le  doses o f m ethotrexate w ere  enro lled in th is  dose 
escalation study. The firs t 32  pa tien ts  w ere  sp lit in to four 
cohorts  of e ight pa tien ts each (six w ere  random ly assigned to  
active trea tm ent and tw o  to  p lacebo). A C Z 8 8 5  doses w ere  0.3,
1, 3 and 10 m g/kg, adm in is tered intravenously on days 1 and
15. To explore e fficacy w ith in  6 w eeks of treatm ent, an
additiona l 21 pa tients  w ere  random ly assigned to  the 10 m g/kg 
cohort, resu lting  in a to ta l o f 20 pa tients dosed w ith  10 m g/kg  
and 15 pa tien ts  trea ted  w ith  p lacebo. There w as clin ica l 
im provem ent (Am erican C o llege  of Rheum ato logy 20 %  
im provem ent criteria) at w eek  6 in the 10 m g/kg  treatm ent 
g roup; however, th is  d id  not reach sta tis tica l s ign ificance  (P  =
0 .085). A  sta tis tica lly  s ign ifican t reduction  in d isease activ ity 
score  w as observed after 4 w eeks in the 10 m g/kg  group. O nset 
of action  w as rapid, because m ost responders exhibited 
im provem ent in the ir sym ptom s w ith in  the  firs t 3 w eeks. C- 
reactive prote in levels decreased in pa tients  trea ted  w ith  
A C Z 8 8 5  w ith in  1 week. A C Z 8 8 5  w as w ell to le ra ted. Three 
pa tients rece iv ing A C Z 8 8 5  deve loped in fectious ep isodes that 
required treatm ent. No an ti-A C Z 8 8 5  an tibod ies w ere  de tected  
during the  study.
Conclusion A C Z 8 8 5  adm in istra tion to  m ethotrexate-re fractory 
pa tients resu lted in clin ica l im provem ent in a subse t o f patients. 
A dd itiona l s tud ies  to  characterize e fficacy in RA and to  
determ ine the  optim al dose regim en appear w arranted.
Trial Registration C lin ica lT ria ls.gov identifie r N C T 0 0 6 1 9 9 0 5 .
ACR =  American College of Rheumatology; CRP =  C-reactive protein; DAS28 =  Disease Activity Score using 28 joint counts; ED50 =  dose effective 
to achieve a mean of 50% improvement; EULAR =  European League Against Rheumatism; h =  human; IL =  interleukin; IL-1 Ra =  IL-1 receptor antag­
onist; RA =  rheumatoid arthritis; TNF =  tumour necrosis factor.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease of 
the jo ints that is associated w ith destruction of cartilage and 
bone. In addition to its local destructive nature, it also can have 
a pronounced system ic inflammatory component, presenting 
as fever, headache and fatigue, and may even affect other 
organs such as the skin, liver, spleen and lymph nodes. The 
contribution made by proinflammatory cytokines such as 
tum our necrosis factor (TNF)-a and IL-1 has been validated in 
preclin ical animal models and in humans [1,2].
Current therapy targeting IL-1 in RA is based on a recombinant 
form of the IL-1 receptor antagonist (IL-1Ra; anakinra), which 
binds to the IL-1 receptor w ithout eliciting a signal and there­
fore com petes w ith the binding of the two natural ligands, 
namely IL-1 a  and IL-1 p. As com pared w ith TNF-a inhibitors, it 
appears that treatm ent w ith the recombinant IL-1Ra is less effi­
cacious in RA [3]. However, it is unclear whether this is due to 
biological superiority of TNF-a over IL-1 in RA pathogenesis
[4] or whether the approach to block the IL-1 receptor with 
anakinra is only partly effective in neutralizing IL-1 activity in 
vivo because of short half-life or inability to achieve sufficient 
exposure at the target site w ith the current dosing regimen [5].
The main e lic itor of inflammatory responses in preclin ical ani­
mal models appears to be IL-1 p and not IL-1 a. In murine co l­
lagen-induced arthritis [6] and antigen-induced arthritis [7,8], 
inflammation and cartilage degradation were inhibited by 
blocking IL-1 p but not IL-1 a. In RA patients, IL-1 p is over­
expressed in inflamed synovial tissue, in particular in the lining 
layer and in sublining cells [9], and it is elevated in draining 
lymph from affected jo ints [10]. Furthermore, IL-1 p is localized 
to the synovial pannus in close proximity to bone and cartilage
[11], and cartilage from arthritis patients exhibits upregulation 
of IL-1 p mRNA as com pared w ith normal cartilage. Increased 
levels of IL-1 p in synovial fluid [1 2] have been described and 
were found to correlate w ith histological features of RA 
[13,14]. Treatment w ith anakinra dem onstrated improvement 
in histological characteristics of RA jo int pathology [15], and 
evidence was provided that it delays the progression of radio­
graphic jo int damage [16]. Thus, there is reason to believe that 
IL-1 p is a crucial cytokine that drives inflammation and joint 
destruction in RA.
W e report here results of preclin ical studies and a proof-of- 
concept study in patients w ith RA, using a fully monoclonal 
antibody (AC Z885) directed against human IL-1 p. A C Z 88 5  is 
expected to have the half-life of a typical IgG 1 antibody, thus 
ensuring full neutralization of IL-1 p over a longer period of time 
as compared w ith recombinant IL-1Ra; the therefore study 
explored pharmacodynamic effects in RA patients (secondary 
to an evaluation of safety).
Materials and methods
In vivo activity of ACZ885 in a human IL-1p-dependent 
mouse model of joint inflammation
Cells of the murine fibroblast line 3T3NIH were transfected 
w ith retroviral vector DFG-hIL-1 p-neo, which contains the 
cDN As fo r human (h)IL-1 p and neomycin phosphotransferase 
(neoR), as described previously [17]. The 3T3NIH fibroblast 
cell line was derived from a DBA background. One clone 
derived from the transduction, namely IB2 (3T3-hIL-1 p), was 
selected, which produced high levels of hIL-1 p (220  ng hIL- 
1p /24  hours per 106 cells) in vitro. hIL-1 p-induced arthritis 
was induced by intra-articular injection of 104 IB2 cells into the 
right knee jo ints of DBA-1 mice. M ice were injected w ith 
A C Z 88 5  or isotype contro l antibody C H I621, which is specific  
for human C D 25 and does not cross-react w ith mouse cells or 
tissue. All mice were housed in filter top cages, and water and 
food were supplied ad libitum. The mice were studied at age 
10 to 14 weeks. All animal experiments were approved by the 
Nijmegen University Animal Ethics Committee.
Adm inistration of antibodies was intraperitoneal 2  hours 
before intra-articular injection of the IB2 clone. Joint inflamma­
tion was quantified using the 99mTc uptake method [18]. By 
external gamma counting, this method measures the accum u­
lation of a small radioisotope at the site of inflammation caused 
by locally increased blood flow  and tissue swelling. The sever­
ity of inflammation is expressed as the ratio of " ^ T c  uptake in 
the right (inflamed) to that in the left (control) knee joint.
Proteoglycan synthesis was assayed as follows. Patellae w ith 
minimal surrounding tissue were placed in RPMI 1640 
medium w ith glutamax, gentamycin (50 |ig /m l) and 35S-sul- 
phate (0.74 M Bq/m l). A fte r 3 hours of incubation at 37 °C  in a 
carbon dioxide incubator, patellae were washed in saline three 
times, fixed in 4%  formaldehyde and subsequently decalcified 
in 5%  form ic acid fo r 4 hours. Patellae were punched out of 
the adjacent tissue, dissolved in 0.5 ml Luma Solve at 65°C  
(Omnilabo, Breda, The Netherlands), and after addition of 10 
ml Lipoluma (Omnilabo) the 35S content was measured using 
liquid scintilation counting. For histological analysis, whole 
knee jo ints were removed and fixed in 4%  formaldehyde fo r 7 
days before decalcification in 5%  form ic acid and processing 
for paraffin embedding. Tissue sections (7 |im ) were stained 
w ith haematoxylin/eosin or safranin O /fast green. H istopatho- 
logical changes in the knee jo ints were scored in the patella/ 
fem ur region on five semi-serial sections, spaced 140 |im 
apart. Scoring was performed on decoded slides by two sep ­
arate observers, using the fo llow ing parameters. In the haema- 
toxylin/eosin stained slides the amount of cells infiltrating the 
synovial lining and the jo int cavity was scored from 0 to 3. Pro­
teoglycan depletion was scored in the safranin O stained 
slides on a scale from 0 to 3 (ranging from stained cartilage to 
fully destained cartilage). Cartilage damage was scored from
0 to 3 (ranging from unaffected cartilage to maximum chondro­
cyte death and cartilage destruction).
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Design of clinical study
This was a randomized, double-blind, placebo-controlled, 
dose escalation study conducted to explore the safety, tolera- 
bility, pharm acokinetics and pharmacodynamics of A C Z 88 5  in 
patients w ith active RA, despite ongoing treatm ent w ith a sta­
ble dose of methotrexate (MTX) of 15 m g/week or more for at 
least 3 months (C A C Z885A 2101). It is the first of its kind to 
be conducted in humans. Patients receiving stable doses of 
10 m g/week methotrexate could be included if the patients 
could not tolerate higher doses.
Included patients were required to have a diagnosis of RA 
(American College of Rheumatology [ACR] 1987 revised 
classification for criteria for RA) w ith a disease duration of at 
least 6 m onths before randomization; active disease at screen­
ing; baseline evaluation (same evaluator) indicating more than 
six tender and six swollen jo ints out of 28 examined (including 
any effused joint); and either W estergren erythrocyte sedim en­
tation rate of 28 m m /hour or greater, or C-reactive protein 
(CRP) of at least 6 mg/l. The inclusion criteria also required 
patients were have failed at least one disease-modifying 
antirheumatic drug in the past, but not deemed 'refractory to 
all therapies'. Their current treatm ent regimen included at least 
15 mg m ethotrexate/week and w ith the current dose stable for 
approximately 3 months. Patients were required to have an 
otherwise stable RA therapeutic regimen, consisting of either 
a stable dose of nonsteroidal anti-inflammatory drugs and/or a 
stable dose of oral corticostero ids (prednisone or equivalent <  
10 mg/day) fo r at least 4 weeks before randomization.
This multicentre study was conducted in accordance w ith 
G C P  (Good Clinical Practice) guidelines and the Helsinki 
Declaration in three countries in Europe. The study protocol 
and patient informed consent form was approved by local eth­
ics com m ittees and health authorities. The primary objective 
was to evaluate the safety and tolerability of A C Z 88 5  adm inis­
tered as an intravenous infusion. Secondary objectives 
included assessment of the preliminary b io logic activity/phar­
macodynamics of A C Z 88 5  using A C R  criteria for clinical 
response and Disease Activity Score using 28 jo int counts 
(DAS28), evaluation of the pharm acokinetics of A C Z 88 5  and 
examination of the potential immunogenicity of A C Z885.
The initial dose escalation phase of the study consisted of four 
cohorts (Figure 1). In each cohort six patients were randomly 
assigned to receive A C Z 88 5  and tw o patients were randomly 
assigned to receive placebo. In the first cohort, patients ran­
domly assigned to A C Z 88 5  received 0.3 m g/kg intravenously 
on days 1 and 15. Safety data from a minimum of six out of 
eight patients in this cohort up to day 20 were reviewed prior 
to proceeding w ith the study and starting the next higher dose. 
Patients randomly assigned to A C Z 88 5  in the second cohort 
received 1 m g/kg, in the third cohort 3 m g/kg, and finally in the 
fourth cohort 10 mg/kg. Safety data from the 10 m g/kg cohort 
were found to raise no concern that m ight prevent proceeding 
w ith the study, so this cohort was extended to increase the 
sample size, such that in total 20 patients received 10 mg/kg 
intravenous on days 1 and 15, and a total of 15 patients 
received placebo. Thus, a total of 53  patients w ith RA were 
enrolled.
Figure 1
t t
10 mg/kg, n=14; pbo=7
Day 1 15 43 113
f t
10 mg/kg, n=6; pbo=2
Day 1 15 20 43 113
t t
3 mg/kg, n=6; pbo=2
Day 1 15 20 43 113
f f
1 mg/kg, n=6; pbo=2
Day 1 15 20 43 113
0.3 mg/kg, n=6; pbo=2
Day 1 15 20 43 113
-----------------------------------------------►
Time
Study design. Sequential dose-escalation, randomized, double-blind, placebo controlled study design with an extension at the highest dose level. 
ACZ885 was administered intravenously on days 1 and 15 (arrows). Safety data generated up to day 20 in each cohort were reviewed before esca­
lating to the next higher dose level. Independent observer efficacy assessments were made at day 1, before dosing, and day 43, in addition to weekly 
investigator assessments up to Day 43. The end of study was on day 113. After safety review of the first six patients at 10 mg/kg, an extension 
cohort was started, which included 14 patients on ACZ885 and seven patients on placebo (pbo).
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A C R  response criteria were evaluated at baseline and on days
8, 15, 22, 29 and 43  by the investigator, and at baseline and 
day 43 by a blinded observer at each site who was not other­
w ise involved in the study. Overall, there was no evidence of a 
system atic bias between the blinded observer and the investi­
gator assessments. Patients were further fo llowed for safety 
and pharm acokinetic assessments, and a formal end of study 
was reached at day 113. Investigators were free to change 
treatm ent after day 43 as they deemed necessary.
Statistical analyses
Statistica l analyses were performed on the A C R  20% , 50%  
and 70%  response criteria (ACR20, A C R 50 and ACR 70) 
rates. Separate statistical analyses were performed on the 
response rate at day 43 (assessed by a blinded observer) and 
the response rate up to and including day 43. Fisher's exact 
test was used to compare treatm ent groups. From these anal­
yses, one sided P  values are presented. The primary com pari­
son was the comparison between the 10 mg/kg treatment 
group and placebo at day 43. For the D AS28 measurements, 
a repeated measures mixed effect analysis was performed. 
Baseline D A S 28 was included in the model as a covariate. An 
unstructured correlation structure was assumed to adjust for 
correlation within patients. From this model the adjusted mean 
difference for each treatm ent group versus placebo at each 
time point was calculated, along within its 95%  confidence 
interval. No m ultiplicity adjustm ents were made to the con fi­
dence intervals. A  similar analysis was performed on the CRP 
measurements; however, because of the skewness of the 
CRP measurements, the analysis was performed on the loge 
scale and results were back-transformed onto the original 
scale.
The inclusion of six patients per dose group in each escalation 
step provided an 80%  probability that at least one patient 
would report an adverse event that has an underlying inci­
dence rate of 24% . W ith  20 patients receiving the highest 
A C Z 88 5  dose (six patients in the last escalation step plus 14 
patients in the expansion phase) and 15 patients receiving pla­
cebo (two patients in each of the four escalation steps plus 
seven patients in the expansion phase), there was at least 
80%  power to detect a statistically significant difference in 
A C R 20 response rate com paring A C Z 88 5  w ith placebo, 
assuming an underlying odds ratio of 6, a 5%  significance 
level and a one-side test approach. Given an anticipated pla­
cebo A C R 20 response rate of 20% , an odds ratio of 6 would 
translate into an A C R 20 response rate of 60%  fo r the 
A C Z 88 5  treatm ent group.
Results
ACZ885 is a human antibody that binds to human IL-1 p 
with high affinity and neutralizes human IL-1 p in vitro 
and in vivo
A C Z 88 5  was derived by subjecting genetically engineered 
mice carrying part of the human immunoglobulin repertoire to
immunization w ith human IL-1 p. The antibody was initially iden­
tified from a hybridoma derived from these mice because of its 
ability to bind human IL-1 p w ith high affinity (about 40 pmol/l). 
No cross-reactivity toward rodent IL-1 p or human IL-1a was 
observed fo r A C Z 885. The antibody was found to neutralize 
the bioactivity of human IL-1 p on primary human fibroblasts in  
vitro w ith an 50%  inhibitory concentration of 44 .6 pm ol/l (7.1 
±  0.56 ng/ml; n =  6).
IL-1 p requires highly potent antagonists in large excess to neu­
tralize its biological activity in vivo. Anti-cytokine antibodies 
w ith low neutralizing capacity can potentially lead to enhanced 
bioactivity of the targeted cytokine by prolonging its half-life in 
vivo [19]. In light of this potential com plication, we considered 
demonstration that A C Z 88 5  is devoid of any biologically rele­
vant carrier effect in an in vivo model to be an important pre­
requisite for conducting clinical trials. Therefore, we created 
an artificial mouse model of jo int inflammation that relies upon 
continuous secretion of human IL-1 p by transfected mouse 
NIH3T3 cells in jected into one knee joint. W hereas IL-1 p 
driven inflammation becomes apparent after 24  hours and 
leads to total destruction of the jo int within 7 to 10 days, con- 
trolateral jo ints or jo ints receiving contro l 3T3 cells do not 
exhibit signs of inflammation. Application of A C Z 88 5  intraperi- 
toneally 2 hours before injecting the IL-1 p producing cells 
com pletely suppressed jo int swelling, w ith a 50%  effective 
dose (the dose effective to reduce inflammation by a mean of 
50% ; ED50) of 0 .06 mg/kg (Figure 2a). Also, treatment w ith 
A C Z 88 5  restored the ability of cartilage explants to synthesize 
proteoglycan, which is otherwise suppressed in IL-1 p exposed 
cartilage (Figure 2 b). In addition, histopathology taken at day 
3 after injection of 3T3-hIL-1 p cells revealed that adm inistra­
tion of A C 8 85  pro tected against severe jo int destruction (Fig­
ure 2c). Apart from the strong reduction of the jo int 
inflammation (numbers of cells in the synovial tissues), no 
bone erosion was noted in the A C 8 85  treated animals com ­
pared w ith controls. Thus, A C Z 88 5  has suffic ient potency to 
neutralize fully the biological activity of human IL-1 p, even 
when it is produced at high concentrations in vivo, and it does 
not significantly prolong IL-1 activity.
Proof-of-concept clinical trial in patients with RA
A proof-of-concept study to explore safety and tolerability, 
pharm acokinetics and pharmacodynamics was conducted in 
patients w ith established RA w ith ongoing disease despite 
stable treatm ent w ith MTX. (Some of the data from this study 
were presented at EULAR [European League Against Rheu­
matism] in 2006  [20].) An overview of patient dem ographics 
at baseline is given in Table 1, and the design of the study is 
presented in Figure 1.
In the 10 m g/kg cohort there were six out of 19 (32% ) A C R 20 
responders at day 43, as assessed by the blinded observer, 
versus one out of 15 (7%) in the placebo group (one-sided P  
=  0 .085; Table 2). A C R 50 and A C R 70 improvements were
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Figure 2
Blocking of IL-1 in mouse models of arthritis. (a) Inhibition of swelling. Mice were given different doses of ACZ885 or a control anti-CD25 antibody 
(CHI621, 12 mg/kg) intraperitoneally before injection of 10,000 3T3-huIL-1 p cells into the right hind knee joint. Swelling was measured 3 days after 
cell injection (as described in Materials and methods) and is expressed as the ratio between the right (treated) and left (untreated) joint. The results 
presented represent the mean ±  standard error or the mean (SEM; n =  5). **P <  0.01 by analysis of variance followed by Dunnett's test for multiple 
comparisons post hoc. NS, not significant. (b) Proteoglycan (PG) synthesis by chondrocytes in explanted patellae was measured by incorporation of 
35S labelled sulphate in isolated cartilage from treated (right) and untreated (left) knee joints. The results are given as the ratio of 35S incorporation 
between right and left knee cartilage and represent the mean ±  SEM (n =  5). Statistical analysis of the treated groups versus the control group 
(CHI621) was performed by analysis of variance followed by Dunnett's test for multiple comparisons post hoc. *P <  0.05; **P <  0.01. ED50, dose 
needed to achieve a mean of 50% effect. (c) Histology was analyzed at day 3 after local injection of 3T3-hIL-1 p producing cells. Section of a mouse 
knee joint treated with isotype control antibody or AC885 are shown. Hematoxylin and eosin staining, original magnification (200x). Quantitative 
evaluation of the slides was done as described in Materials and methods and is presented in the graph. n =  5 joints per group; all comparisons 
between active and control were significant (P <  0.05, Mann-Whitney U-test).
observed at the highest dose levels (3 and 10 m g/kg) in a total 
of four out of 25 patients, but no such responses were 
observed in the placebo group. Using the investigator assess­
ments, 10 out of 20 patients (50% ) achieved an A C R 20 and 
four out of 20 an A C R 50 or better response at any time point 
up to and including day 43 (Table 2). There was a statistically 
significant difference com pared w ith placebo in terms of 
A C R 20 improvement when all A C Z 88 5  cohorts (one-sided P  
=  0 .043) or when the 3 mg/kg and 10 m g/kg cohorts were
pooled (one-sided P  =  0.035). Nine out of the 10 AC R 20 
responders satisfied criteria fo r response within 3 weeks after 
the first infusion. The time to achieve an A C R 50 response was 
1 week in one patient, 3 weeks in a second patient, and 4 
weeks in two patients. Under placebo, three out of 15 patients 
exhibited an observable A C R 20 response during the 6-week 
period of observation. One patient had an A C R 20 response 
after 1 week, which disappeared thereafter. A  second patient 
had an A C R 20 response at weeks 1 and 3 but not on any
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Tab le  1
Baseline demographics of participating patients
Characteristic ACZ885
0.3 mg/kg (n =  6) 1.0 mg/kg (n =  6) 3.0 mg/kg (n =  6) mg/kg (n =  20) Placebo (n =  15)
Age (years; mean ±  SD) 61 ±  7 53 ±  14 57 ±  7 50 ±  11 55 ±  10
hsCRP (mg/l; median [range]) 17.8 (1.6-95.3) 43.8 (5.8-89.3) 3.0 (2.0-43.4) 11.1 (1.5-28.4) 6.4 (0.2-66.2)
DAS28 (mean ±  SD) 6.5 ±  0.8 6.6 ±  1.2 6.7 ±  1.5 6.2 ±  0.7 6.7 ±  0.6
Number of tender joints (mean ±  SD) 17 ±  9.2 15 ±  6.2 22 ±  8.5 17 ±  7.3 20 ±  6.3
Number of swollen joints (mean ±  SD) 
Methotrexate dose (n/mg median [range])a
13 ±  6.3 12 ±  4.3 12 ±  7.4 11 ±  4.8 12 ±  5.2
Oral 6/17.5 (15-25) 5/15 (10-15) 4/15 (15-15) 13/15 (10-22.5) 5/15 (10-20)
Parenteral 0 1/10 (10-10) 2/22.5 (20-25) 7/15 (10-22.5) 10/15 (10-25)
aNumbers of patients receiving 15 mg/week were 2, 4, 4, 10 and 6 in the 0.3, 1, 3, 10 mg/kg and placebo cohorts, respectively. SD, standard 
deviation.
other occasion. The third patient had an A C R 20 response 
after 3 weeks which continued after day 43.
Figure 3a shows the mean reduction in D AS28 in the cohort 
treated w ith 10 mg/kg as com pared w ith placebo. The P  val­
ues for the treatm ent com parisons at days 29 and 43 were 
0 .024  and 0.081, respectively. Using the EULAR response cri­
teria, a subset of five out of 20 patients treated w ith 10 mg/kg 
A C Z 88 5  achieved a good response, and 10 out of 20 
achieved a moderate response at any time point up to and 
including day 43 under 10 mg/kg. Four out of five patients who 
were classified as good responders achieved the necessary 
D A S 28 reduction within the first 3 weeks of treatment, indicat­
ing a rapid onset of action.
The fact that about 50%  of all patients exhibited clinical benefit 
w ithin the first 6 weeks of treatm ent prom pted us to analyze 
CRP levels under therapy as a potential marker of response 
versus nonresponse. As shown in Figure 3b, there was a sub­
stantial mean reduction in and normalization of CRP within a 
few  days after com m encing treatm ent w ith 10 mg/kg 
A C Z 885. Similarly, CRP was also reduced upon treatm ent in 
the other active treatm ent cohorts (data not shown). As dem ­
onstrated in Table 3 for the 10 m g/kg cohort, a reduction in 
CRP at day 43 was required to achieve a A C R 20 or higher 
response; however, eight subjects had a more than 50%  
reduction in CRP but had no detectable clinical response 
based on A C R 20 criteria. Thus, CRP levels declined under 
A C Z 88 5  treatm ent in the majority of patients (14 /1 8  patients
Table 2
Clinical improvement as assessed by ACR criteria
Assessor (time point) Response ACZ885 Placebo 
(n =  15)
P  value
(10 mg/kg versus 
placebo)
0.3 mg/kg 
(n =  6)
1.0 mg/kg 
(n =  6)
3.0 mg/kg 
(n =  6)
10 mg/kg 
(n =  19/20a)
Blinded observer 
(day 43)
ACR20 1 (17%) 0 (0%) 4 (67%) 6 (32%) 1 (7%) 0.085
ACR50 0 (0%) 0 (0%) 1 (17%) 3 (16%) 0 (0%) 0.162
ACR70 0 (0%) 0 (0%) 0 (0%) 2 (11%) 0 (0%) 0.305
Investigator
(any time within 6 weeks of treatment start)
ACR20 3 (50%) 2 (33%) 4 (67%) 10 (50%) 3 (20%) 0.070
ACR50 0 (0%) 0 (0%) 2 (33%) 4 (20%) 0 (0%) 0.093
ACR70 0 (0%) 0 (0%) 0 (0%) 3 (15%) 0 (0%) 0.174
Shown are the number and percentage of patients achieving 20%, 50%, or 70% improvement in terms of American College of Rheumatology 
(ACR) criteria (ACR20, ACR50 and ACR70, respectively) at day 43 as assessed by a blinded observer and at any time point within 6 weeks of 
treatment start as assessed by the investigator. aNote that for one patient in the 10 mg/kg treatment group, the ACR criteria assessment by a 
blinded observer was not conducted at day 43.
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Figure 3
Reduction in disease activity and CRP levels following ACZ885 ther­
apy in RA patients. (a) Mean disease activity (Disease Activity Score 
using 28 joint counts [DAS28]) levels over time. Baseline adjusted 
mean and standard error of the mean (SEM) from the repeated meas­
ures analysis are presented for patients treated with ACZ885 10 mg/ 
kg (n =  20) and placebo (n =  15). P  values for comparison of ACZ885 
10 mg/kg versus placebo at each time point are presented. (b) Geo­
metric mean C-reactive protein (CRP) levels over time. Baseline 
adjusted mean and SEM from the repeated measures analysis are pre­
sented after transformation back onto the original scale for patients 
treated with ACZ885 10 mg/kg (n =  20) and placebo (n =  15). P  val­
ues for comparison of ACZ885 10 mg/kg versus placebo at each time 
point are presented. Normal range of CRP was 0 to 8.4 mg/l.
amenable for analysis), but only six of the CRP responders 
achieved an A C R 20 response at day 43. W ith in  the placebo 
cohort (Table 3), the majority of patients (n =  10) did not 
exhibit any meaningful CRP reduction (<20% ); however, CRP 
was reduced by more than 5 0 %  in three patients, but this was 
not associated w ith an A C R 20 response.
The serum concentrations of A C Z 8 8 5  were determ ined in 
each dose group. The maximal concentration rose in a dose-
proportional manner and reached a mean peak exposure of 
329  |ig /m l in the 10 m g/kg group after the second infusion, 
which decreased to less than 10 |ig /m l by day 113. The 
elim ination half-life was similar across all dose levels and aver­
aged 21 .5  ±  4.9 days (mean ±  standard deviation). Details of 
exposure and its relationship to pharmacodynamic activities of 
A C Z 8 8 5  will be reported elsewhere.
Safety and tolerability
During the study five serious adverse events leading to hospi­
talization were identified. Am ong them, two events in the 10 
m g/kg dose group (fracture of the left trochanter major after a 
bicycle fall and one case of tracheobronchitis) and one in the
0.3 m g/kg group (potential recurrence of angina pectoris) 
were considered not to be related to the study medication. 
Two episodes identified in the 1 m g/kg dose group (one case 
of erysipelas and one case of pulmonary infection) were con­
sidered to be related to study medication. All patients with 
infectious events were treated w ith antibiotics and recovered 
fully w ith in the expected time frame. None of the patients pre­
maturely discontinued treatment because of adverse events. 
There were no infusion-related adverse events; in particular, 
no anaphylactic or anaphylactoid reactions were reported. 
Serum samples were tested for the presence of an ti-A C Z885 
antibodies at baseline, on days 43 and 71, and at the end of 
the study (day 113). No form ation of an ti-A C Z885 antibodies 
was detected at any time point during the study.
The overall adverse event profile was almost the same for 
active and placebo treatment. Headache was reported less 
frequently w ith A C Z 885  treatment (28 .9%  versus 46 .7%  for 
placebo), and urinary tract infection was reported frequently 
often w ith A C Z 885  (21%  versus 6.7%  fo r placebo). Overall, 
intravenous administration of A C Z 88 5  up to 10 m g/kg given 
tw ice w ith 14 days between dosing was found to be well to l­
erated w ithout evidence of immunogenicity.
Discussion
A C Z 885, a novel human monoclonal antibody directed 
against human IL-1 p, was found to be highly active in inhibiting 
IL-1 p mediated arthritis in a preclin ical animal model. The low 
ED50 observed in this model of aggressive inflammation is 
remarkable, because the injected recombinant cells constitu­
tively secrete human IL-1 p w ithout any physiological feedback 
control. These results prom pted us to study A C Z 88 5  in a 
dose-escalating, proof-of-concept study in patients w ith RA -  
the first of its kind in humans. The study's primary objective 
was to investigate safety and tolerability; therefore, it was not 
powered to investigate efficacy or to draw firm conclusions 
regarding superiority or inferiority to treatment w ith anakinra or 
TNF blockers in RA. The small sample size of 38  patients 
treated w ith various doses of A C Z 885  and 15 patients on pla­
cebo does not allow any definitive conclusion about safety to 
be drawn. W hether an increase in infectious episodes under 
A C Z 885  represents an early sign of the consequences of
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Tab le  3
Relationship between CRP reduction and ACR response following ACZ885 treatm ent
Group CRP reduction at day 43 versus baseline ACR response at day 43 
<20%  20% to <50% 50% or more
10 mg/kg ACZ885 <20% 4 0 0
20 to <50% 0 1 1
50% or more 8 2 2
Placebo <20% 9 1 0
20 -  <50% 2 0 0
50% or more 3 0 0
Relationship between C-reactive protein (CRP) reduction and American College of Rheumatology (ACR) response at day 43 for patients in the 10 
mg/kg group and patients receiving placebo. Note that two subjects are excluded from the 10 mg/kg ACZ885 because of missing data.
blocking IL-1 -  sim ilar to observations w ith anakinra [21] -  
needs confirmation, and careful monitoring in upcoming larger 
studies is required. Immunogenicity and infusion-associated 
events were not observed w ith two intravenous 
administrations.
The study provides evidence of a treatment effect by dem on­
strating that 50%  of patients achieved an A C R 20 response up 
to day 43 in the highest tested dose of 10 m g/kg intravenous, 
along w ith a robust reduction in serum CRP. No firm conclu­
sion regarding any dose-response relation can be drawn, 
because of the small sample size (n =  6) of the cohorts treated 
w ith 0.3, 1, and 3 m g/kg A C Z 885. The onset of action in those 
who responded was found to be rapid. The majority of these 
responders satisfied the EULAR criteria for moderate or good 
response or A C R 20 response criteria within 3 weeks. Sim ilar 
to experience w ith other b iologics fo r the treatm ent of RA 
patients, there was a subset of patients who did not respond 
to treatment. On the other hand, some patients achieved an 
A C R 50 or even A C R 70 response within a short period of 
treatment. This observation reflects the common understand­
ing that RA represents a heterogeneous disease and that, 
even by applying stric t inclusion criteria, the studied disease in 
clinical trials is not homogenous. Therefore, a better under­
standing of the pathophysiology on an individual basis is 
required if we are to better predict the response to a certain 
treatm ent and hence avoid treatm ent failures. Consequently, 
there is a need to establish biomarkers that have high pred ic­
tive value; recent progress has been made fo r TNF blockers 
[22,23].
In the current study, CRP reduction was found to be neces­
sary for achievment of clinical response, as expected, but it 
was not suffic ient to explain or even predict clinical response, 
because CRP reduction was also observed in the absence of 
clinical response. Therefore, CRP reduction during treatment 
does not serve as a predictive biomarker fo r c linical responses 
at the individual level. Furthermore, levels of serum IL-6, TNF- 
a  and IL-1Ra levels (as measured by enzyme-linked immuno­
sorbent assay) were within the normal range in these patients 
and exhibited no conclusive changes during the course of the 
study (data not shown). A t baseline, total IL-1 p levels in serum 
were at or below the detection limit of the assay (about 1 pg / 
ml) and showed no difference between responders and non­
responders, indicating that baseline serum levels of these 
cytokines are of poor predictive value to identify treatment 
responders.
A lm ost all rheum atologists prefer to adm inister a TNF blocker 
rather than anakinra as a first b iologic agent to treat RA 
patients, concordant w ith a recent consensus statement, and 
national and international registries [3]. Treatment w ith recom ­
binant IL-1Ra (anakinra) has been shown to be effective in RA 
[24], but its efficacy appears to be lower than that of TNF-a 
inhibitors [25] and its adm inistration is frequently associated 
w ith injection-related adverse events. W hether anakinra's 
lower efficacy is due to an inferior b io logic role of IL-1 as com ­
pared w ith TNF-a in the pathogenesis of RA or is simply due 
to the fact that anakinra cannot fully neutralize IL-1 is currently 
unclear. A C Z 88 5  can com pletely neutralize IL-1 p over a long 
period of time; it therefore offers an opportunity to study the 
relative biological role of IL-1 p in the pathogenesis of RA. Fur­
ther and larger studies will determ ine the efficacy of A C Z 885  
in treating signs and symptoms in patients w ith RA, and they 
may allow  comparison w ith the efficacies of other biologic 
agents.
Conclusion
A C Z 88 5  was found to inhibit IL-1 p mediated jo int inflamma­
tion in preclin ical models. It was well tolerated in this first 
p roof-of-concept study in RA patients and was associated 
w ith a significant treatm ent effect in about 50%  of patients. 
Further studies are warranted to confirm these initial results, to 
establish a safety profile, to identify those patients who will 
profit most from blocking IL-1 p, and to better understand the 
biological role played by IL-1 p in the pathogenesis of RA.
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